anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Foodborne diseases are common sources of morbidity and mortality worldwide. Scombroid syndrome represents a particular condition since it is not directly related to the ingestion of spoiled food but is determined by high levels of histamine, a chemical mediator naturally produced within the human body under particular conditions. In these cases, histamine is formed as a result of the bacterial activity from histidine, an amino acid present at high levels in some fish species. The resulting symptomatology can range from mild symptoms such as headache and skin rash to more severe manifestations such as hypotension and coronary spasms. Reference regulations in Italy set maximum levels of histamine in food at 200 mg/kg.
CASES DESCRIPTION: The cases described involve a family of three who, following the ingestion of a tuna dish, started to exhibit symptoms typical of an allergic reaction. In one case, hypotension, tachycardia, and electrocardiographic changes in the ST-tract suggestive of myocardial ischemia also appeared with negative myocardionecrosis enzyme dosage. All three cases experienced complete remission of symptoms in the absence of sequelae. Histamine concentrations in fish sampled three days later were 169 mg/kg.
CONCLUSION: The cases described emphasize the importance of proper differential diagnosis as well as the importance of implementing specific controls in food hygiene.
Patients visiting one of the study clinics prior to implementation of the CHIMES intervention. The Baseline time period consists of study Months 1 - 12. Data are retroactively abstracted from medical records of patients who had clinic visits that occurred between January 1, 2019 and December 31, 2019.
Classical target-based drug screening is low-throughput, largely subjective, and costly. Phenotypic screening based on in vitro models is increasingly being used to identify candidate compounds that modulate complex cell/tissue functions. Chronic inflammatory nociception, and subsequent chronic pain conditions, affect peripheral sensory neuron activity (e.g., firing of action potentials) through myriad pathways, and remain unaddressed in regard to effective, non-addictive management/treatment options. Here, a chronic inflammatory nociception model is demonstrated based on induced pluripotent stem cell (iPSC) sensory neurons and glia, co-cultured on microelectrode arrays (MEAs). iPSC sensory co-cultures exhibit coordinated spontaneous extracellular action potential (EAP) firing, reaching a stable baseline after ≈27 days in vitro (DIV). Spontaneous and evoked EAP metrics are significantly modulated by 24-h incubation with tumor necrosis factor-alpha (TNF-α), representing an inflammatory phenotype. Compared with positive controls (lidocaine), this model is identified as an "excellent" stand-alone assay based on a modified Z' assay quality metric. This model is then used to screen 15 cherry-picked, off-label, Food and Drug Administration (FDA)-approved compounds; 10 of 15 are identified as "hits". Both hits and "misses" are discussed in turn. In total, this data suggests that iPSC sensory co-cultures on MEAs may represent a moderate-to-high-throughput assay for drug discovery targeting inflammatory nociception.
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease - NAFLD) is a chronic liver condition linked to obesity and metabolic syndrome. It affects one-third of people globally and, in some cases, can lead to metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis, NASH) and fibrosis. Weight loss is crucial for the treatment of MASLD, but diet and lifestyle modifications often fail.
AREAS COVERED: In recent years, endoscopic sleeve gastroplasty (ESG) has gained popularity as an effective and minimally invasive option for obesity treatment, with widespread use worldwide. We present a current overview of the most significant studies conducted on ESG for the management of obesity and MASLD. Our report includes data from published studies that have evaluated the impact of ESG on noninvasive hepatic parameters used to estimate steatosis and fibrosis. However, at present, there are no data available on liver histology.
EXPERT OPINION: ESG has shown promising results in treating MASLD evaluated by noninvasive tests, but current data is limited to small, nonrandomized studies. More research is needed, particularly on the effects of ESG on histologically proven MASH. If future research confirms its efficacy, ESG may be incorporated into treatment guidelines in the future.
The training, which is prepared based on the motivational interview method, will be given individually, starting when baby is 4 months old, will be interviewed once a week for nine weeks. In first meeting; before starting motivational interview, mothers were interviewed face-to-face with the Baby, Mother Introductory Information Form, Mothers', Babies' Food Consumption Frequency Registration Form, Microbiota Awareness Scale (MFI), Infant Nutrition Attitude Scale (LOWA), Behavior Change Stage Diagnostic Form, Motivational Interview rating the schedule will be applied. At the end of this meeting, which lasts for 45-50 minutes, next meeting date will be determined, the meeting will be terminated. Second interview is planned to last 60-90 minutes. After the second meeting, Motivational interviews will provide information on nutritional posters, brochures of the Ministry of Health, complementary nutrition, nutrition for microbiota. The scales to be used will be re-administered.
UNLABELLED: To understand whether the bone loss which occurs after vertical sleeve gastrectomy increases the risk of fracture, we used an engineering model to estimate risk in participants before and after surgery. We found that estimated risk decreased 1 year after surgery and remained lower, though had rebounded, at year 2.
PURPOSE: Vertical sleeve gastrectomy (VSG) improves metabolic health in young people with obesity but is accompanied by substantial loss of bone mass and estimated bone strength. We thus estimated fracture risk following VSG using the load-to-strength ratio (LSR), which integrates bone strength estimates with the predicted force of a fall.
METHODS: Prospective 2-year study of youth ages 13-24 years with obesity undergoing VSG (n = 24) or lifestyle therapy (n = 34). We performed high-resolution peripheral quantitative computed tomography of the distal radius and microfinite element analysis to estimate bone strength and calculated LSR.
RESULTS: VSG participants lost 26.4 ± 8.1% weight at year 1 (p < 0.001), which was sustained at year 2, while control participants gained weight at year 2 (4.5 ± 8.3%, p = 0.009). The predicted impact force decreased at years 1 and 2 following VSG (p < 0.001) but increased at year 2 among controls (p = 0.011). Estimated bone strength was unchanged at year 1 but decreased (p < 0.001) at year 2 following VSG, while bone strength did not change in controls. At year 1, the LSR decreased among VSG participants (p < 0.001), implying a lower risk of fracture. At year 2, the LSR was lower than baseline (p < 0.001), but higher compared to year 1 (p = 0.001). LSR did not change in the control group.
CONCLUSIONS: Short-term estimated fracture risk at the radius following VSG decreases. However, ongoing bone loss despite stable weight between years 1 and 2 leads to a concerning rise in estimated fracture risk. Longer follow-up will be critical to evaluate the trajectory of fracture risk. (ClinicalTrials.gov NCT02557438, registered 9/23/2015).
It is intended to provide an IRAP (insulin responsive aminopeptidase)-binding protein, etc. More particularly speaking, an IRAP-binding protein, drugs containing this protein, a method of screening a compound inhibiting the binding of this protein to IRAP, compounds obtained by the screening method, etc. are provided.  The above-described protein is useful as, for example, preventives and remedies for hypoglycemia. This protein is also useful as a reagent for screening a compound inhibiting the binding of the protein to IRAP or GLUT4 (glucose transporter 4). Compounds inhibiting the binding of this protein to IRAP or GLUT4 are useful as, for example, preventives and remedies for hyperglycemia, diabetes, etc.
Research has been inconclusive as to whether stimulant treatment causes or exacerbates sleep problems in adolescents with ADHD. This study examined sleep differences in adolescents with ADHD as a function of stimulant use. Participants were adolescents with ADHD (N = 159, ages 12-14). Parents reported on receipt of stimulant treatment (n = 92, 57.86%; n = 47 amphetamines, n = 45 methylphenidate). Adolescents wore actigraphs and completed daily diaries assessing sleep and daily use of stimulants for 2 weeks. Sleep parameters included daily-reported bedtime, sleep onset latency (SOL), sleep duration, daytime sleepiness, and difficulty waking the following morning; and actigraphy-measured sleep onset time, total time in bed, and sleep efficiency. We estimated between- and within-individual associations between stimulant medication use and sleep indices with all stimulants, after removing adolescents using sleep aids and weekend days, and as a function of stimulant type. Adolescent sleep did not differ between those receiving and not receiving stimulant treatment. Within individuals using stimulants, we largely observed no significant differences between medicated and unmedicated days, though findings were most often significant for school days only. Small effects were found indicating longer SOL, later sleep onset time, and more daytime sleepiness related to medication use. In contrast, there were slight improvements to sleep duration and sleep efficiency related to methylphenidate use, though methylphenidate was also associated with later sleep onset time and more daytime sleepiness. Given the inconsistent and small effects, findings suggest that stimulant medication may impact sleep, but does not appear to be a primary contributor to sleep problems in adolescents with ADHD.
Study design is a single-blind examination of the analgesic effects of a single dose of seven test medications provided in an experimental pain paradigm using a cold pressor test (CPT). Test medication conditions include buprenorphine, morphine, hydromorphone, hydrocodone, oxycodone, and two placebo conditions to match test medication formulations (oral tablet, sublingual tablet). Each medication condition will be tested on separate days (seven total days, completing within 12 weeks), with random assignment to order of study medications. After screening, eligible participants will be scheduled for 7 days of testing with test days at least 3 days apart to provide a sufficient medication wash-out period. Pain testing will utilize cold pressor tests (CPT), in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance. Participants will be given a practice trial to provide familiarity with the test and reduce test anxiety. Two CPTs will occur on each test day, and pre- and post-CPT assessments will be administered. Blood samples will be taken on each test day to measure blood levels of buprenorphine. Daily procedures include: (1) A baseline CPT (BL-CPT), (2) Administration of the test medication (active drug or placebo), (3) CPT administered at the time of maximum drug effect (Tmax-CPT) specific to medication (range 30-120 minutes), (4) Pupillometry conducted at baseline (before BL-CPT), and at time of maximum drug effect (before Tmax-CPT). Each participant will be discharged after clinical determination of the participant's safety and well-being. Testing will continue until twelve trials of each medication condition are completed.
208,154. Stern, L., and Battelli, F. Dec. 6, 1922, [Convention date]. Medicines for internal use; medicines for external application.-Hormones or internal secretions are obtained from glands such as the supravenal capsules by removing the gland immediately after the death of the animal and keeping the gland tissue alive in a nutritive liquid, such as defibrinated blood from an animal of the same species or a physiological salt solution or the like, at a temperature of 40‹ C. in the presence of oxygen. The hormone continues to he secreted and accumulates in the liquid, and may be isolated therefrom bv the usual methods. Small pieces of gland tissue may be suspended in the nutritive liquid. The Specification as open to inspection under Sect 91 (3) (a) states also that the whole gland may be subjected to artificial circulation with the nutritive liquid. This subject-matter does not appear in the Specification as accepted.
Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
During the preoperative upper endoscopy, the EndoFLIP catheter is inserted through the mouth with endoscopic guidance and placed through the gastric pylorus. Once deployed, water is sequentially added at set volumes to a balloon that can be used to measure pyloric diameter, cross-sectional area, pressure, and distensibility at set volumes of 30, 40, and 50 mL for at least five seconds. We will record this data for each patient. The EndoFLIP catheter will then be removed. Subsequently, a high resolution ADM catheter will be inserted through the nose and placed through the pylorus to measure baseline intragastric, transpyloric, and intraduodenal pressures. The patient will be observed for up to four hours to assess a migrating motor complex (MMC). After the MMC is observed, the patient will be given a meal and observed for meal response with the manometry catheter. The meal will be water and two pieces of toast/bread. Following the meal, the catheter will be removed.
Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Bipolar disorder may begin as depression or mania, which can affect the treatment and prognosis. The physiological and pathological differences among pediatric bipolar disorder (PBD) patients with different onset symptoms are not clear. The aims of the present study were to investigate subcortical structural alterations in PBD patients with first-episode depressive (PBD-FED) and first-episode manic (PBD-FEM).
METHODS: A total of 59 individuals including 28 PBD-FED, 13 PBD-FEM, and 18 healthy controls (HCs) underwent high-resolution structural magnetic resonance scans. FreeSurfer 7.2 was used to detect changes in subcortical volumes. Simultaneously, thalamic, hippocampal, and amygdala subregion volumes were compared between the three groups.
RESULTS: Analysis of covariance controlling for age, sex, education, and estimated intracranial volume shows third and fourth ventricle enlargement in patients with PBD. Compared with the PBD-FED and HCs, the PBD-FEM group had reduced gray matter volume in the left thalamus, bilateral hippocampus, and right amygdala. Subsequent subregion analyses showed right cortico-amygdaloid transient, bilateral accessory-basal nucleus, left hippocampal tail, right hippocampal head, and body volume reduction in the PBD-FEM group.
CONCLUSIONS: The present findings provided evidence of decreased subcortical structure in PBD-FEM patients, which might present its trait feature.
<P>PROBLEM TO BE SOLVED: To provide an easy to swallow oral medicament composition.  <P>SOLUTION: The easy to swallow pharmaceutical composition consists of one or several coated particles with a core which contains an active substance and a coating with one or several layers. The coating layers (one or more layers) contain at least one hydratable, pharmaceutically acceptable polymer which is in contact with saliva or water forms a coherent, moldable, viscous mass with a slippery surface which does not adhere to the mucous membranes of the mouth and which prevents the active substance-containing particles from leaving the mass and releasing the active substance in the mouth cavity. The coating layer or the outermost coating layer contains an effective amount of at least one salivation promoting agent. The formation of a moldable, slippery mass and the taste-masking properties of the coating make the composition suitable in particular for administering highly dosed or bad tasting active substances, and can preferably be swallowed even without any liquid.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To produce titled glass adequate as a dental material without having defects such as cracks by subjecting a glassy casting formed by adding F atoms to the compsn of a ternary component system of CaO-Al2O3-P2O5 to multiple stages of crystallization treatments while heating up the casting. CONSTITUTION:F atoms are added to a raw material mixtue of the compsn. composed of 10-60wt% CaO, 5-35wt% Al2O3 and 25-85wt% P2O5 at <=3pts. wt. by 100pts.wt. in total of the above-mentioned compsn. The mixture is melted and cast to produce the glassy casting. The glassy casting is subjected to >=2 stages of the crystallization treatment while the temp. is gradually increased between the softening point thereof and the crystallization temp. of calcium phosphate. The melting of Al2O3 at the lower temp. is made possible by the incorporation of the F atoms into the compsn.; in addition, the cleaning up of the raw material is made easy and the time when the glass is kept melted is shorter; further the formation of crystal nuclei is accelerated in the crystallization stage of the glass. The titled glass having no voids and cracks is obtd. by multiple stages of the crystallization treatments.
A method for a predictive prognosis of the onset of a woman's menopause is described. The method comprises the steps of accessing woman's genetic data comprising the Single Nucleotide Polymorphisms SNPs of the woman; then, processing the aforesaid woman's genetic data, to obtain a predictive prognosis of menopause onset in relation to at least one phenotype F DJ , F CK ; finally, providing as a result the aforesaid predictive prognosis of menopause onset in relation to the at least one phenotype. The aforesaid at least one phenotype F DJ , F CK  comprises at least one age group or an age limit with respect to which the predictive prognosis of menopause onset is to be carried out, or an indication of a woman's age at which the menopause onset is more likely. The aforesaid step of processing the woman's genetic data comprises, for each of the phenotypes considered F DJ , F CK , the following steps: identifying, in the woman's genetic data, a first personalized subset Sh of Single Nucleotide Polymorphisms SNPs which also belong to a first predetermined set h, associated with the phenotype considered; each of the Single Nucleotide Polymorphisms SNPs of such a first predetermined set h comprises an identifier of Single Nucleotide Polymorphisms SNPs, and is associated with a respective pre-calculated first relevance parameter β 1(Fn),i;  then, calculating a first value PRS1(F n ) of polygenic risk score, based on the first personalized subset Sh of Single Nucleotide Polymorphisms SNPs and the respective first pre-calculated relevance parameters β 1(Fn),i;  then, determining the predictive prognosis of menopause onset in relation to each of the phenotypes considered FDJ, FCK, based on the respective first value PRS1(F n ) of polygenic risk score. The method provides that the determination of the first predetermined set h of Single Nucleotide Polymorphisms SNPs and the calculation of the first relevance parameters β 1(Fn),i  are carried out in a preliminary training step, which is independent from the aforesaid step of accessing woman's genetic data and prior to the aforesaid step of processing the woman's genetic data. Such a preliminary training step comprises training at least one algorithm (A) by means of machine learning and/or artificial intelligence techniques, based on known data.
A woman in her 70s presented with anasarca and exertional dyspnoea. Investigation showed severe hypoalbuminaemia with no urinary or gastrointestinal protein losses. CT thorax reported lung consolidations, and transbronchial lung biopsy demonstrated organising pneumonia. Autoimmune myositis serology was positive for anti-Jo-1, anti-Ro-52, and anti-PM/Scl-100 antibodies. She was diagnosed with anti-synthetase syndrome with organising pneumonia. She was treated with oral prednisolone and oral mycophenolate mofetil with a good clinical response.
Participants will be administered a stimulant medication (Adderall IR 10mg). The ordering of experimental vs. placebo appointments will be counterbalanced. Participants will complete computer-based tests of sustained attention and working memory during all appointments.
Electrophysiological Effects

The effect of dronedarone on 12-lead ECG parameters was investigated in healthy subjects following repeated oral doses up to 1600 mg twice daily for 10 days. Concentration-dependent increases in QTcF and PR were observed and the estimated increases for 400 mg BID with food are 15 and 12 ms, respectively. The contribution of dronedarone and the N-debutyl metabolite to observed changes is unknown.

DAFNE Study

DAFNE was a dose-response study in patients with recurrent AF, evaluating the effect of dronedarone in comparison with placebo in maintaining sinus rhythm. The doses of dronedarone in this study were 400, 600, and 800 mg twice a day. In this small study, doses above 400 mg were not more effective and were less well tolerated.
The present invention relates to virulent (lytic)  Listeria monocytogenes  phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and/or shipped, in order to reduce  Listeria monocytogenes  contamination. P100 can also be used in the present invention to identify  Listeria monocytogenes  bacteria present on (or within) foodstuffs, as well as those  Listeria monocytogenes  bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with  Listeria monocytogenes . The phage and the endolysin of the present invention can also be used to treat animals infected with  Listeria monocytogenes . P100 will kill the bacteria that are within its host range with great efficiency and will propagate to high titer thereon. P100 can be combined with other lytic phage, and/or with other antimicrobial agents to reduce or eliminate  Listeria.
Ganciclovir is a synthetic guanine derivative active against cytomegalovirus (CMV).

Ganciclovir is available as 250 mg and 500 mg capsules. Each capsule contains 250 mg or 500 mg ganciclovir, USP respectively, and inactive ingredients croscarmellose sodium, FD&C blue #2, gelatin, iron oxide black, iron oxide yellow, lecithin, magnesium stearate, microcrystalline cellulose, povidone, shellac, simethicone, and titanium dioxide.

Ganciclovir is a white to off-white crystalline powder with a molecular formula of C9H13N504 and a molecular weight of 255.23. The chemical name for ganciclovir is 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine. Ganciclovir is a polar hydrophilic compound with a solubility of 2.6 mg/mL in water at 25° C and an n-octanol/water partition coefficient of 0.022. The pKas for ganciclovir are 2.2 and 9.4. The molecular structure of ganciclovir is:

All doses in this insert are specified in terms of ganciclovir.